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Mesenteric fat belongs to visceral fat. An increased deposition of mesenteric fat contributes to obesity associated complications
such as type 2 diabetes and cardiovascular diseases. We have investigated the therapeutic effects of bardoxolone methyl (BARD)
on mesenteric adipose tissue of mice fed a high-fat diet (HFD). Male C57BL/6J mice were administered oral BARD during HFD
feeding (HFD/BARD), only fed a high-fat diet (HFD), or fed low-fat diet (LFD) for 21 weeks. Histology and immunohistochemistry
were used to analyse mesenteric morphology and macrophages, while Western blot was used to assess the expression of
inflammatory, oxidative stress, and energy expenditure proteins. Supplementation of drinking water with BARD prevented
mesenteric fat deposition, as determined by a reduction in large adipocytes. BARD prevented inflammation as there were fewer
inflammatory macrophages and reduced proinflammatory cytokines (interleukin-1 beta and tumour necrosis factor alpha). BARD
reduced the activation of extracellular signal-regulated kinase (ERK) and Akt, suggesting an antioxidative stress effect. BARD
upregulates energy expenditure proteins, judged by the increased activity of tyrosine hydroxylase (TH) and AMP-activated protein
kinase (AMPK) and increased peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1𝛼), and uncoupling
protein 2 (UCP2) proteins. Overall, BARD induces preventive effect in HFD mice through regulation of mesenteric adipose
tissue.
1. Introduction
Obesity is associated with an increased likelihood of chronic
diseases such as cardiovascular disease, type 2 diabetes, high
blood pressure, and fatty liver disease. It is believed that the
mesenteric adipose tissue is important in the pathogenesis
of obesity [1–4]. Mesenteric adipose tissue is drained via the
portal vein, which delivers fatty acids and proinflammatory
cytokines secreted by this tissue to the liver. Studies have
shown that this can cause local and systemic inflammation [2]
as well as an interruption in insulin action leading to severe
insulin resistance in liver [5–7]. Additionally, an increase
in mesenteric adipose tissue is linked to inflammation and
oxidative damage in vascular tissue and to metabolic syn-
drome in the gastrointestinal tract and liver [3, 8, 9]. Reports
have shown that mesenteric adipose tissue is an independent
determinant of metabolic syndromes in humans [10, 11].
Changes inmesenteric fatmorphology (adipocyte expan-
sion), an increased level of inflammation and oxidative stress,
and reduced energy metabolism are all features of mesen-
teric fat in obesity. Studies have shown that the mesenteric
adipose tissue of high-fat diet (HFD) induced obese mice
has an increase in number of large-sized adipocytes [8, 12].
Additionally, obese mice and humans have a greater number
of infiltrating macrophages and increased proinflammatory
cytokines such as interleukin-1 beta (IL-1𝛽) and tumour
necrosis factor alpha (TNF-𝛼) in mesenteric adipose tissue
[8, 13, 14].The recruitment of anti-inflammatorymacrophage
phenotype (M2) to inflammatory macrophage phenotype
(M1) in mesenteric adipose tissue is linked to colitis, hepatic
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steatohepatitis, insulin resistance, and development of obesity
[15, 16]. Moreover, it has been shown that the increased
fat deposition and proinflammatory cytokines in visceral fat
depots generate reactive oxidative stress, which in turn esca-
lates inflammation and obesity [17–20].
The positive energy balance that drives obesity is a con-
sequence of impaired energy metabolism. In peripheral
tissues, AMP-activated protein kinase (AMPK) is an energy
sensor involved in energymetabolism andwhole body energy
homeostasis via the integration of nutrient, hormone, and
stress signals [21–24]. Reduced AMPK activity has been
widely observed in obesity in vivo and in vitro [25, 26].
The reduction of AMPK also reduces energy regulation by
peroxisome proliferator-activated receptor gamma coacti-
vator 1-alpha (PGC-1𝛼) and uncoupling protein 2 (UCP2)
molecules in many peripheral tissues, including mesenteric
fat, skeletal muscle, and liver [27–29]. These changes result
in increased adiposity, stress, and inflammation [26, 30].
Moreover, the reduction in noradrenergic and adrenergic
activity is linked to reduced thermogenesis, increased body
weight, and development of obesity [31–33]. We have found
that HFD mice had reduced level of energy expenditure
proteins including 𝛽
3
adrenergic receptor (𝛽
3
-AR), UCP2,
and tyrosine hydroxylase (TH, a noradrenergic marker) in
adipose tissues and the brainstem [34, 35].
Certain plants (e.g., olives, apples, and ginseng) are used
as oriental medicine because of their ability to produce
pharmacologically active compounds, such as pentacyclic
triterpenes [36–38]. Triterpenes have demonstrated benefits
in the treatment of obesity, inflammatory diseases, and cancer
in humans and rodents. These compounds exert antiobesity
effects by suppressing blood pressure, fat deposition, and
body weight gain and increasing energy expenditure [39–41].
Increasing evidence has demonstrated the suppressive effect
of pentacyclic triterpenes (oleanolic acid, ursolic acid, and
betulinic acid) on visceral fat in obesity [41–43].
Bardoxolone methyl (BARD) is a synthetic pentacyclic
triterpenoid compound derived from oleanolic acid. There
is an increasing body of evidence showing that BARD mod-
ulates oxidative stress and inflammation via suppressing
inflammatory signalling pathway and proinflammatory cy-
tokines while activating anti-inflammatory antioxidant sig-
nalling pathway [44–46]. Moreover, BARD has been ob-
served to benefit the immune system, brain, and peripheral
tissues, including the kidneys, lungs, liver, colon, and white
adipose tissue [47–51]. BARD has been used to treat obesity
in humans and obese mice [49, 52]. Although BARD has
been shown to induce heart failure in chronic kidney disease
patients [53], this compound and its analogs are effective in
obese mouse models and humans [52, 54]. Previously, we
have reported the benefits of BARD in preventing obesity-
associated complications (cognition and inflammation) in
the brain and peripheral tissue of HFD-fed mice [34, 35, 50,
55]. In white fat, particularly, oral BARD prevents fat deposi-
tion and invasion of macrophages, inflammatory cytokines,
and stress activated proteins in epididymal adipose tissue
[35]. Moreover, reports from previous study and our research
have indicated the involvement of BARD in energy regulation
[34, 35, 49].
We have shown that HFD induces changes in metabolic
and inflammatory processes in epididymal adipose tissue of
mice and that BARD improves this tissue [35]. However,
it has been mentioned that mesenteric adipose tissue has
responded differently to HFD compared with epididymal
adipose tissue [56]. Additionally, specific effects of BARD
on mesenteric adipose tissue are not clear; we continue to
investigate the health benefits of oral BARD in this tissue of
HFD-fed mice. The outcome of this study will provide more
information on understanding the pharmacological benefits
of BARD in preventing obesity-related disorders through
multiple effects on adipose tissue, which has been mentioned
in our previous reports [34, 35].
2. Materials and Methods
2.1. Experimental Procedures on Animals. The experimental
procedures on animals were assessed and approved by the
Animal Ethics Committee of the University of Wollongong,
NSW, Australia. Male C57BL/6J mice were obtained from
the Animal Resource Centre, Perth, WA, Australia. After
1 week of acclimatisation to the institutional animal facil-
ity (temperature 22∘C, 12 h light/dark cycle), the animals
were divided into three groups (𝑛 = 7): (1) mice fed
a normal diet (LFD group) (Vella Stock Feeds, Doonside,
NSW, Australia); (2) mice fed a high-fat diet (HFD group)
(40% fat) (SF11-095, Speciality Feeds, WA); and (3) mice fed
the same HFD and supplemented with BARD in drinking
water (10mg/kg body weight) (HFD/BARD group). The
dose and oral administration of BARD were chosen based
upon previous studies [49, 57]. We found that HFD mice
administered BARD had smaller body weight compared with
HFD control as per our previous report [35]. After 21 weeks,
all mice were euthanized using CO
2
asphyxiation. Part of the
mesenteric fat mass in each animal was collected and stored
at −80∘C for Western blot analysis. Another portion of the
mesenteric fat depot was fixed in 4% paraformaldehyde and
embedded in paraffin for the determination of morphology
and immunohistochemistry.
2.2. Histology and Immunohistochemistry. Paraffin-embed-
ded sections of mesenteric adipose tissue were cut (4 𝜇m)
and stained with haematoxylin and eosin (POCD Scientific,
Artarmon, NSW, Australia). Microphotographs (×40) were
then taken of the stained sections using a Leica microscope.
The size and number of mesenteric adipocytes were quanti-
fied by ImageJ 1.46r software (National Institute of Health,
Bethesda, MD, USA), which is based upon our previous
reports [34, 35].
Immunohistochemistry was used to determine the den-
sity of macrophages including total (F4/80), inflammatory
(CD11c), and anti-inflammatory (CD206) phenotype in mes-
enteric adipose tissue. Method is based upon our previous
report [35]. Briefly, paraffin-embedded sections of themesen-
teric fat were cut at 4 𝜇m and antigens retrieved in sodium
citrate buffer (10mM, pH 6.0) and processed for im-
munohistochemical staining. Sections were probed with
either anti-F4/80 (ab6640), anti-CD11c (ab33483), or anti-
CD206 (ab64693). Secondary antibodies are rabbit anti-rat
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IgG biotinylated secondary antibody (ab6733), goat anti-
Armenian Hamster IgG H&L biotin (ab5744), or goat anti-
rabbit IgG H&L biotin (ab6720). All antibodies were pur-
chased from Abcam Inc., Cambridge, MA, USA. Micropho-
tographs were taken using a Leica microscope (×40). The
quantification of macrophages is described in our previous
reports [34, 35].
2.3. Western Blot Analysis. We used Western blot to detect
the expression of different proteins including inflammatory
cytokines and energy expenditure proteins following the
technique reported in a previous study of ours [58]. Mesen-
teric adipose tissue was homogenised in NP-40 lysis buffer
supplemented with protease inhibitor cocktail, 𝛽-glycerol
phosphate, and phenylmethanesulfonyl fluoride (PMSF).The
protein concentration of the extracted lysates was determined
using the BCAProteinAssay (PierceChemical Co., Rockford,
IL, USA). Homogenates (25 𝜇g protein) were dissolved in
Laemmli buffer with 5% 2-mercaptoethanol, resolved on
4–12% Bis Tris-HCl gels, and transferred to polyvinyli-
dene difluoride (PVDF) membranes (Bio-Rad Laboratories,
Gladesville, NSW, Australia). The membranes were blocked
in 5% bovine serum albumin before incubation with pri-
mary antibodies overnight at 4∘C. The primary antibodies
used were IL-1𝛽 (sc-7884), TNF-𝛼 (sc-8301), 𝛽
3
-AR (sc-
1473), UCP2 (sc-6525), PGC-1𝛼 (sc-13067), pJNK (sc-6254),
and pAkt1/2/3 (sc-33437) from Santa Cruz Biotechnology
(Dallas, TX, USA); hydroxylase phosphoSer 40 (AB5935),
tyrosine hydroxylase (AB9983), and actin (MAB1501) from
MerckMillipore (Kilsyth, Victoria, Australia); I𝜅B-𝛼 (#9242),
pSTAT3 (#9145), pERK1/2 (#4370), AMPK𝛼 (#2532), and
phospho-AMPK𝛼 (#2535) from Cell Signaling Technology
(Beverly, MA, USA). The following day samples were incu-
bated with the appropriate secondary antibody for 1 hour,
which were one of the following: goat anti-rabbit (AP307P)
and goat anti-mouse (AP308P) from Chemi-Con Interna-
tional, Inc. (Temecula, CA, USA), and donkey anti-goat (sc-
2033) from Santa Cruz Biotechnology (Dallas, TX, USA).
Protein bandswere visualised using enhanced chemilumines-
cence and quantified using Quantity One software (Bio-Rad
Laboratories, Hercules, CA, USA) with normalisation to 𝛽-
actin.
2.4. Statistical Analysis. The SPSS 19 package (SPSS, Chicago,
IL, USA) was used for data analysis. One-way analysis
of variance (ANOVA) test followed by a least significant
difference (LSD) post hoc analysis was used to analyse adipose
tissue histology, F4/80macrophage density, proinflammatory
cytokines, and energy expenditure proteins. All values were
performed as mean ± SEM. Statistical significance was
considered at 𝑝 < 0.05.
3. Results
3.1. BARD Prevents Mesenteric Fat Deposition in HFD-Fed
Mice. We examined the effect of BARD on the size and num-
ber ofmesenteric adipocytes inHFDmice (Figure 1(a)). HFD
mice had threefold increase in mesenteric adipocyte size
(𝑝 < 0.001) compared with LFD mice (Figure 1(b)). How-
ever, BARD supplementation during HFD induced twofold
decrease in the size of mesenteric adipocytes (𝑝 < 0.001)
compared with HFD control. In contrast to the increased
cell surface area, the number of adipocytes was significantly
reduced by three times (𝑝 < 0.001) in HFD mice compared
with LFD mice (Figure 1(c)). Compared with HFD mice,
the number of mesenteric adipocytes in HFD/BARD was
doubled (𝑝 < 0.001). Additionally, Figure 1(d) demonstrates
a shift in adipocyte size distribution inHFD-fedmice towards
a smaller size with BARD treatment. The size distribution
of adipocytes was similar between HFD/BARD and LFD
mice. This data provides evidence that BARD prevents fat
deposition in mesenteric adipose tissue.
3.2. BARD Prevents Infiltration and Recruitment of Inflamma-
tory Macrophages in Mesenteric Adipose Tissue of HFD Fed
Mice. To investigate anti-inflammatory effect of BARD, we
initially examined the presence of infiltrating macrophages
(F4/80) by immunohistochemistry (Figure 2(a)). Compared
with LFD mice, HFD mice had a marked increase in the
number of F4/80 crown-like structures (+95%; 𝑝 < 0.001),
which was effectively prevented by BARD (−50%; 𝑝 <
0.01) (Figure 2(b)). Similarly, the number of F4/80 interstitial
macrophages was significantly higher in HFD mice by 98%
(𝑝 < 0.001) compared with LFD mice and by 32% (𝑝 <
0.01) compared with HFD/BARD mice (Figure 2(c)). In
Figure 2(c), the density of inflammatory (M1) and anti-
inflammatory (M2) macrophage phenotype was also identi-
fied, assessed by the positive staining of CD11c and CD206
cells. HFD mice had threefold increase in number of CD11c
positive macrophages compared with LFD mice (𝑝 < 0.001).
The number of these cells was reduced by five times when
the HFD mice were administered BARD (𝑝 < 0.001). In
contrast, HFD mice had reduced number of CD206 positive
macrophages by 67% (𝑝 < 0.001) compared with LFD mice.
HFD mice treated with BARD had 155% increase in number
of CD206 positive cells (𝑝 < 0.001). BARD suppresses the
infiltration and recruitment of inflammatory macrophages,
suggesting an anti-inflammatory effect.
3.3. BARD Suppresses Proinflammatory Cytokines and Oxida-
tive Stress Proteins in Mesenteric Adipose Tissue of HFD-Fed
Mice. Figure 3(a) shows that HFD mice had increased level
of IL-1𝛽 protein (+66%;𝑝 < 0.001) comparedwith LFDmice.
This protein was reduced by 32% (𝑝 < 0.01) when the HFD
mice were supplemented with BARD. While a small but not
statistically significant increase in TNF-𝛼 was also observed
in HFD mice compared with LFD mice (+15%; 𝑝 = 0.19),
BARD supplementation reduced the expression of TNF-𝛼 by
26% (𝑝 < 0.05) compared with HFD mice (Figure 3(b)).
Nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha, or I𝜅B-𝛼 (which is negatively associated
with inflammation) was also determined in the present study
but no significant difference was found (Figure 3(c)). The
reduced expression of proinflammatory cytokines in the
present study further suggests an anti-inflammatory effect of
BARD.
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Figure 1: Effect of bardoxolone methyl (BARD) on mesenteric fat deposition of mice fed low-fat diet (LFD), high-fat diet (HFD), and high-
fat diet supplemented with BARD (HFD/BARD). (a) Haematoxylin and eosin stained sections (×40). Bar = 50 𝜇m. (b) Mesenteric adipocyte
area. (c) Number of cells per high power field (HPF). (d) Distribution of adipocyte size. All data are presented as mean ± SEM. ∗𝑝 < 0.05;
∗∗
𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
In this study, we examined the effect of BARD on oxida-
tive stress signalling by assessing the stress activated proteins
including phosphorylated protein kinase B (pAkt), phospho-
rylated extracellular signal-regulated kinase (pERK), phos-
phorylated signal transducer and activator of transcription
3 (pSTAT3), and phosphorylated c-Jun N-terminal kinase
(pJNK) in mesenteric adipose tissue. In Figure 4(b), mice fed
a HFD had 56% increase in pAkt compared with those fed a
LFD (𝑝 < 0.05). On the other hand, BARD administration
induced 54% reduction in pAkt protein (𝑝 < 0.01). As shown
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Figure 2: Effect of bardoxolone methyl (BARD) on expression of F4/80, CD11c, and CD206 macrophages in mesenteric adipose tissue of
mice fed low-fat diet (LFD), high-fat diet (HFD), and high-fat diet supplemented with BARD (HFD/BARD). (a) F4/80, CD11c, and CD206
stained sections (×40). Bar = 50𝜇m. The asterisks indicate F4/80 crown-like structures (CLS); the arrow heads demonstrate single F4/80,
CD11c, and CD206 positive stained cells. (b) Number of CLS per high power field (HPF). (c) Number of F4/80, CD11c, and CD206 positive
cells per HPF. All data are presented as mean ± SEM. ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
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Figure 3: Effect of bardoxolone methyl (BARD) on expression of proinflammatory cytokines in mesenteric adipose tissue of mice fed low-
fat diet (LFD), high-fat diet (HFD), and high-fat diet supplemented with BARD (HFD/BARD). (a) Representative blots and protein level
of IL-1𝛽. (b) Representative blots and protein level of TNF-𝛼. (c) Representative blots and protein level of I𝜅B-𝛼. All data are presented as
mean ± SEM. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001. IL-1𝛽: interleukin-1 beta, TNF-𝛼: tumour necrosis factor alpha, I𝜅B-𝛼: nuclear factor of
kappa light polypeptide gene enhancer in B-cells inhibitor alpha, and AU: arbitrary unit.
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Figure 4: Effect of bardoxolone methyl (BARD) on expression of stress activated proteins in mesenteric fat tissue of mice fed low-fat diet
(LFD), high-fat diet (HFD), and high-fat diet supplemented with BARD (HFD/BARD). (a) Representative blots and protein level of pSTAT3.
(b) Representative blots and protein level of pAkt. (c) Representative blots and protein level of pERK. (d) Representative blots and protein
level of pJNK. All data are expressed as mean ± SEM. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001. pSTAT3: phosphorylated signal transducer
and activator of transcription 3, pAkt: phosphorylated protein kinase B, pERK: phosphorylated extracellular signal-regulated kinase, pJNK:
phosphorylated c-Jun N-terminal kinase, and AU: arbitrary unit.
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in Figure 4(c), HFD mice had a significant increase in pERK
by 50% (𝑝 < 0.01) compared to LFD mice. However, BARD
reduced pERK by 50% (𝑝 < 0.001) in HFD mice. There
were no statistical differences in pSTAT3 and pJNK among
three groups ofmice (Figures 4(a) and 4(d), resp.).These data
demonstrate that BARD prevents the increase of pAkt and
pERK which occurs in HFD-fed mice, suggesting that BARD
suppresses oxidative stress-induced by HFD.
3.4. BARDEnhances EnergyMetabolism inMesenteric Adipose
Tissue of HFD-Fed Mice. We first investigated the effect of
BARD on noradrenergic activation, assessed by expression of
TH protein and phosphorylation. There was no significant
difference in protein expression of total TH among mouse
groups (Figure 5(a)). Compared with LFD- and HFD-fed
mice, HFD mice administered BARD had increased level
of phosphorylated TH (pTH) protein by 46% (𝑝 < 0.05)
and 80% (𝑝 < 0.01), respectively (Figure 5(b)). Consistently,
pTH/TH ratio in HFD/BARD mice was increased by 39%
(𝑝 < 0.05) compared with LFD mice and by 23% (𝑝 = 0.08)
compared with HFD mice (Figure 5(c)). The effect of BARD
on adrenergic activation and mitochondrial uncoupling was
also assessed via the protein expression of 𝛽
3
-AR and PGC-1𝛼
and UCP2. There was no significant difference in expression
of 𝛽
3
-AR protein among mouse groups (Figure 5(d)). The
HFD mice showed a significant decrease in protein expres-
sion of PGC-1𝛼 (−22%;𝑝 < 0.05) andUCP2 (−33%;𝑝 < 0.05)
compared with the LFD mice (Figures 5(e) and 5(f), resp.).
ComparedwithHFDcontrol,HFDmice administeredBARD
had significant increase in PGC-1𝛼 protein by 24% (𝑝 < 0.05)
and in UCP2 protein by 30% (𝑝 < 0.05).
We also further investigated the effect of BARD on the
protein expression of total AMPK and its phosphorylation
(Figure 6(a)). Figure 6(b) shows that HFD induced a signif-
icant decrease in total AMPK protein (−25%; 𝑝 < 0.05)
compared with LFD mice. However, compared with HFD
mouse control, those administered BARD had significant
increase in total AMPK protein by 24% (𝑝 < 0.05). In
Figure 6(c), mice fed a HFD had reduced phosphorylated
AMPK (pAMPK) protein by 37% (𝑝 < 0.05) compared with
those fed a LFD. Compared with HFDmice, pAMPK protein
in HFD/BARD mice was increased by 80% (𝑝 < 0.01).
Similarly, HFDmice administered BARD had increased level
of pAMPK/AMPK ratio by 34% (𝑝 < 0.05) compared with
LFD mice and by 75% (𝑝 < 0.01) compared with HFD mice
(Figure 6(d)). Taken together, these data suggest that BARD
improves energy metabolism in mesenteric adipose tissue of
HFD-fed mice.
4. Discussion
In the present study we investigated the effect of oral BARD
at 10mg/kg body weight, administered daily in drinking
water on the mesenteric adipose tissue of mice fed HFD.
The data demonstrate that BARD can suppress HFD induced
fat deposition, inflammation, and oxidative stress, and it
enhances energy metabolism in mesenteric adipose tissue.
Increasing evidences have shown that HFD induces
increase of body weight and fat deposition in various tissues
[56, 59] and changes in cellularity (cell size and number) are
characteristic of obesity [8, 60]. Presently, we found that
BARD increased the number and distribution of small adi-
pocytes in mesenteric fat of HFD-fed mice. Studies have
shown a reduction in the number of large-sized adipocytes
and an increase in the number of small-sized adipocytes
in adipose tissue is correlated to improved insulin sensi-
tivity and reduced obesity-induced insulin resistance [61–
63]. Consistently, we have found that BARD prevents insulin
resistance in mice on HFD [55]. Similarly, the preventive
effect of BARD on fat deposition in epididymal and brown
adipose tissue suggests that BARD may prevent obesity-
related insulin resistance and diabetes mellitus through reg-
ulation of adipocytes. Evidences have shown that BARD and
its analogues reduce fat mass in obesemousemodels [49, 54].
This is also consistent with the reducing effect of BARD on
body weight, which was mentioned in our previous report
and other studies [35, 52]. The effect of BARD is consistent
with the antiobesity function of pentacyclic triterpenes [41–
43]. The present study provides the first data of the effect of
BARD on mesenteric fat deposition and suggests that this
molecule has potential in preventing visceral obesity.
In obesity mesenteric adipose tissue becomes inflamed,
demonstrated by the infiltration of immune cells (macro-
phages), which leads to a proinflammatory immune response
(increased production of proinflammatory cytokines) [3, 64].
In the present study, BARD administration reduced the infil-
tration of inflammatory macrophages and proinflammatory
cytokine expression in HFD-fed mice, suggesting an anti-
inflammatory effect. This is consistent with its derivative
oleanolic acid, which reduces F4/80 positive macrophage
infiltration in the kidneys of C57BL/6 mice affected by oxi-
dative stress [65]. In another study BARD reduced the num-
ber of infiltrating alveolar macrophages in lung tissue by 40%
in bleomycin treated C57BL/6 mice [48]. Similarly, we
have shown that BARD reduces M1 macrophage phenotype
(CD11c) and increases M2 macrophage phenotype (CD206)
in BAT of HFD-fed mice [34]. In the present study, BARD
suppresses the expression of proinflammatory cytokines
within mesenteric adipose tissue of HFD mice. Obesity is
characterised by low-grade inflammation, reflected, in part,
by increased expression of circulating (TNF-𝛼) and local
(TNF-𝛼, IL-1𝛽) proinflammatory cytokines in diet-induced
obese mice [66–68]. Present data, thus, demonstrate anti-
inflammatory property of oral BARD through suppression
of proinflammatory cytokines. Previously, BARD treatment
reduced the mRNA expression of IL-1𝛽, TNF-𝛼, and IL-6 in
the liver and epididymal fat of diet-induced diabetic mice
[49]. Since the upregulation of proinflammatory cytokines
and inflammatory macrophage phenotype (i.e., CD11c) in
mesenteric adipose tissues relates to the development of col-
itis, inflammation, and steatohepatitis in liver, insulin resist-
ance [15, 16], it seems that BARD provides health benefits in
HFD mice.
Escalated level of protein kinases including protein kinase
B (Akt), extracellular signal-regulated kinase (ERK), signal
transducer and activator of transcription (STAT), and c-
Jun N-terminal kinase (JNK) has been observed in HFD-
fed mice. We found an increased level of pAkt and pERK
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Figure 5: Effect of bardoxolone methyl (BARD) on expression of rate limiting enzyme, 𝛽
3
-AR, PGC-1𝛼, and UCP2 in mesenteric adipose
tissue of mice fed low-fat diet (LFD), high-fat diet (HFD), and high-fat diet supplemented with BARD (HFD/BARD). (a) Representative
blots and protein level of TH. (b) Representative blots and protein level of pTH. (c) pTH/TH ratio. (d) Representative blots and protein level
of 𝛽
3
-AR. (e) Representative blots and protein level of PGC-1𝛼. (f) Representative blots and protein level of UCP2. All data are expressed
as mean ± SEM. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01. TH: tyrosine hydroxylase, pTH: phosphorylated TH; 𝛽
3
-AR: 𝛽
3
-adrenergic receptor; PGC-1𝛼:
peroxisome proliferator-activated receptor gamma coactivator 1-alpha; UCP2: uncoupling protein 2; AU: arbitrary unit.
in HFD mice which were suppressed by BARD. Activation
of Akt and ERK is linked to oxidative stress in adipocytes
and in the development obesity-associated complications
[69, 70]. In visceral fat, a greater protein level of oxidative
stress molecules and ERK has been observed in obese
women, when compared to healthy women [20]; the reduced
ERK protein by BARD may indicate an antioxidative func-
tion. BARD reduces nephritis in mice through suppression
of AKT/ERK/NF-𝜅B signaling [71]. BARD induces anti-
inflammatory and antioxidative effects in HFD mice in
our study, which is consistent with the pharmacological
function of BARDand its related compounds (oleanolic acid),
which induce antioxidant anti-inflammatory properties via
activating antioxidant response element- (ARE-) Kelch ECH
associating protein 1- (Keap1-) nuclear factor erythroid 2-
related factor 2 (Nrf2) network [44, 47, 72, 73]. A study
on cardiac cells has shown that ERK activation suppresses
Nrf2, leading to oxidative stress-induced insulin resistance
in vitro and in vivo [74]. The reducing effect of BARD on
ERK and associated Akt activity, therefore, is an indicator for
antioxidative stress of this compound. Previously, we have
found that BARD suppresses the expression of ERK, Akt,
STAT3, and JNK proteins in epididymal adipose tissue of
HFD-fed mice [35]. Additionally, BARD analog, dihydro-
2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO)-
trifluoroethyl amide (dh404), suppresses ERK activity in the
hearts of streptozotocin-induced diabetic mice and diabetic
patients, which is associated with the reduced oxidative stress
and improved insulin sensitivity [74]. From the outcome of
the present study, further research on various stress oxidative
stress genes and signalling pathways will help to understand
antioxidative function of BARD in diet-induced obesity.
Reduced level of TH and its activity in the brain and
peripheral tissues is linked to reduced energy expenditure
and obesity [31, 75, 76]. Presently, BARD induces nonra-
dreneric activation through increasing the activity of rate
limiting enzyme TH. We have found that BARD consis-
tently increases TH signalling activity in epididymal and
brown adipose tissue and the brainstem of HFD-fed mice
[34, 35]. Previous study has reported that the increase of
TH activity in mesenteric adipose tissue is associated with
the increased catecholamine biogenesis and production in
this tissue [77]. In the present study, BARD also increases
PGC-1𝛼 and UCP2 protein in mesenteric adipose tissue of
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Figure 6: Effect of bardoxolone methyl (BARD) on expression of AMPK protein and its activity in mesenteric adipose tissue of mice fed
low-fat diet (LFD), high-fat diet (HFD), and high-fat diet supplemented with BARD (HFD/BARD). (a) Representative blots. (b) Protein level
of AMPK. (c) Protein level of phosphorylated AMPK. (d) pAMPK/AMPK ratio. All data are expressed asmean ± SEM. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01.
AMPK: AMP-activated protein kinase; pAMPK: phosphorylated AMPK; AU: arbitrary unit.
HFD-fed mice. Recent reports on human pluripotent stem
cell have shown that PGC-1𝛼 performs as transcriptional
regulator of mitochondrial biogenesis and is involved in
cellular respiratory events and energy production [78, 79].We
have observed the increasing effect of oral BARD on PGC-1𝛼
protein in the brainstem of HFD-fed mice [34]. Additionally,
increased UCP2 protein was observed in visceral fat of
obesity resistant A/J and C57BL/KsJ (KsJ) mouse strains fed
a HFD, and studies have described the possible role of UCP2
in energy metabolism [79–82]. Previously, mitochondrial
uncoupling has been proposed as mechanistic mechanism
for the antiobesity effect of ursolic acid in HFD-fed mice
[83]. Similarly, we have previously reported the upregulation
of UCP2 protein in epididymal adipose tissue of HFD-fed
mice administered BARD [35]. An in vitro study on muscle
cells has shown that the increased expression of PGC-
1𝛼 protein is linked to the activation of mitochondrial
uncoupling and increased oxygen consumption [84]. These
data, therefore, are an indicator for the involvement of
BARD in the control of energy expenditure. Moreover, we
found that BARD increased total AMPK protein and its
phosphorylation in mesenteric adipose tissue of HFD-fed
mice. AMPK directly stimulates energy expenditure in the
peripheral tissues [85–87]. Reports have implicated AMPK
in energy regulation in visceral fat, and induction of this
molecule results in resistance to obesity [30, 80]. Previously,
BARD treatment activates AMPK in the muscle and the liver
of obese mice fed HFD, which is associated with increased
12 The Scientific World Journal
oxygen consumption and the amelioration of obesity in mice
fedHFD [49]. From the outcome of this study, we suggest that
BARD enhances energy metabolism through activation of
noradrenergic and AMPK activity, mitochondrial biosynthe-
sis, and mitochondrial uncoupling, thus providing a defence
against obesity. Since evidence for the increase of energy
expenditure by BARD has been previously reported [49],
present study provides potential metabolism contributing to
the enhancing effect of BARD on thermogenesis.
The study is the first to provide evidence that BARD
regulates mesenteric adipose tissue in HFD-fed mice by pre-
venting fat deposition and inducing the anti-inflammatory
and antioxidant effect while enhancing energy metabolism.
In particular, BARD administration significantly reduced
the number of large-sized adipocytes while it increased the
number of small adipocytes, suggesting its preventive effect
on fat deposition. In addition, it reduces number of infil-
trating macrophages and recruitment of M1 macrophages,
which were accompanied by reduction of proinflammatory
cytokines and stress activated protein, suggesting its anti-
inflammatory and antioxidative stress effect of BARD. On
a mechanistic level, BARD enhanced energy expenditure
through increasing the activity of rate limiting enzymes TH
and AMPK.This was accompanied by the induction of PGC-
1𝛼 and UCP2 protein. The improving effect of BARD on
metabolic and inflammatory processes in present study is
consistent with the suppressive effect of BARD on body
weight, thus it may link to its antiobesity effect. Overall, the
present study suggests the potential of oral BARD in prevent-
ing visceral fat pathology in obesity. From outcome of present
study and our previous reports [34, 35, 50, 55], we proposes
the regulatory role of BARD in adipose tissues, which would
be an important factor for body weight suppression of this
compound. Further studies will help not only to clarify
our observations but also to warrant further applications of
BARD in humans who are susceptible to obesity.
Conflict of Interests
The authors declare that there is no conflict of interests.
Acknowledgment
The authors would like to thank Diabetes Australia Research
Trust for the support granted to Professor Xu-Feng Huang.
References
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